deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 6-arm NCT03228667

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Sponsor: ImmunityBio, Inc.

Conditions Cervical Cancer Colorectal Cancer Gastric Cancer Head and Neck Squamous Cell Carcinoma Hepatocellular Carcinoma Melanoma Merkel Cell Carcinoma Microsatellite Instability Mismatch Repair Deficiency Non-Small Cell Lung Cancer Renal Cell Carcinoma Small Cell Lung Cancer Urothelial Carcinoma
Interventions N-803 + Atezolizumab N-803 + Atezolizumab + PD-L1 t-haNK N-803 + Avelumab N-803 + Avelumab + PD-L1 t-haNK N-803 + Docetaxel + Nivolumab N-803 + Docetaxel + Pembrolizumab N-803 + Durvalumab N-803 + Durvalumab + PD-L1 t-haNK N-803 + Nivolumab N-803 + Nivolumab + PD-L1 t-haNK N-803 + Pembrolizumab N-803 + Pembrolizumab + PD-L1 t-haNK
Updated 30 times since 2017 Last updated: Jan 13, 2026 Started: Dec 11, 2018 Primary completion: Aug 31, 2029 Completion: Dec 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cervical Cancer and Colorectal Cancer, this trial is ongoing. The trial is conducted by ImmunityBio, Inc. and has accumulated 30 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Apr 2023 · 11 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

30 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  5. Feb 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

▶ Show 25 earlier versions

  1. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  2. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  7. May 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  8. Sep 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  11. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  12. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  13. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  14. Oct 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  15. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  16. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  17. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  18. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  19. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  20. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  21. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  22. Feb 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    Status: Recruiting → Not Yet Recruiting

  23. Nov 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  24. Sep 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE2

  25. Aug 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ImmunityBio, Inc.
Data source: ImmunityBio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anchorage, United States , Billings, United States , Boston, United States , Buffalo, United States , Charleston, United States , Cleveland, United States , Detroit, United States , El Segundo, United States , Fountain Valley, United States , Gettysburg, United States and 24 more locations